Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV
Shumway, David
Dynport Vaccine Company, LLC, Frederick, MD, United States
Search 14 grants from David Shumway
Search grants from Dynport Vaccine Company, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Phosphorylation of FGF23 coordinates crosstalk between the skeleton and kidney
Administrative Core
ADAPT - Comprehensive Care
Structure-Function Analysis of Enveloped Viruses
Mathematical Sciences: Joint Summer Research Conferences in the Mathematical Sciences, 1990-1993
Recently added grants:
Advanced MRI Evaluation of Abdominal Aortic Aneurysms
Harnessing the anabolic potential of Wnt signaling to improve bone health
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction
mTOR-Mediated Desaturation of Fatty Acids in Hepatic Insulin Resistance.
Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic Cancer
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201500005I-5-27200003-1
Application #
9719521
Study Section
Project Start
2016-08-23
Project End
2019-06-28
Budget Start
Budget End
Support Year
Fiscal Year
2018
Total Cost
Indirect Cost
Institution
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Comments
Be the first to comment on David Shumway's grant